



Biomédica
ISSN: 0120-4157
Instituto Nacional de Salud

Vargas-Restrepo, Felipe; Sabogal-Guáqueta, Angélica María; Cardona-Gómez, Gloria Patricia
Quercetin ameliorates inflammation in CA1 hippocampal region
in aged triple transgenic Alzheimer's disease mice model.

Biomédica, vol. 38, no. 1, 2018, pp. 62-69
Instituto Nacional de Salud

DOI: 10.7705/biomedica.v38i0.3761

Available in: <http://www.redalyc.org/articulo.oa?id=84356697009>

- How to cite
- Complete issue
- More information about this article
- Journal's homepage in redalyc.org



Scientific Information System Redalyc
Network of Scientific Journals from Latin America and the Caribbean, Spain and Portugal
Project academic non-profit, developed under the open access initiative

ARTÍCULO ORIGINAL

Quercetin ameliorates inflammation in CA1 hippocampal region in aged triple transgenic Alzheimer's disease mice model.

Felipe Vargas-Restrepo, Angélica María Sabogal-Guáqueta, Gloria Patricia Cardona-Gómez

Área de Neurobiología Celular y Molecular, Grupo de Neurociencias de Antioquia,
Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia

Introduction: Alzheimer's disease is the most common form of dementia. It is characterized by histopathological hallmarks such as senile plaques and neurofibrillary tangles, as well as a concomitant activation of microglial cells and astrocytes that release pro-inflammatory mediators such as IL-1 β , iNOS, and COX-2, leading to neuronal dysfunction and death.

Objective: To evaluate the effect of quercetin on the inflammatory response in the CA1 area of the hippocampus in a 3xTg-AD male and female mice model.

Materials and methods: Animals were injected intraperitoneally with quercetin every 48 hours during three months, and we conducted histological and biochemical studies.

Results: We found that in quercetin-treated 3xTg-AD mice, reactive microglia and fluorescence intensity of A β aggregates significantly decreased. GFAP, iNOS, and COX-2 immunoreactivity also decreased and we observed a clear tendency in the reduction of IL-1 β in hippocampal lysates.

Conclusion: Our work suggests an anti-inflammatory effect of quercetin in the CA1 hippocampal region of aged triple transgenic Alzheimer's disease mice.

Key words: Alzheimer disease; quercetin; microglia; astrocytes.

doi: <https://doi.org/10.7705/biomedica.v38i0.3761>

La quercetina disminuye la inflamación en la región CA1 del hipocampo en un modelo de ratón triple transgénico para la enfermedad de Alzheimer.

Introducción. La enfermedad de Alzheimer es la forma más común de demencia; se caracteriza por la presencia de marcadores histopatológicos, como las placas seniles y los ovillos neurofibrilares, así como por una activación concomitante de células microgliales y astrocitos que liberan mediadores proinflamatorios, como IL-1 β , iNOS y COX-2, lo cual conduce a la disfunción y la muerte neuronal.

Objetivo. Evaluar el efecto de la quercetina sobre la reacción inflamatoria en el área CA1 del hipocampo en un modelo de ratones 3xTg-AD.

Materiales y métodos. Los animales se inyectaron intraperitonealmente con quercetina cada 48 horas durante tres meses, y se hicieron estudios histológicos y bioquímicos.

Resultados. Se encontró que en los animales 3xTg-AD tratados con quercetina, la microglía reactiva y la intensidad de fluorescencia de los agregados A β disminuyeron significativamente, y que hubo una menor reacción de GFAP, iNOS y COX-2, así como una clara tendencia a la reducción de la IL-1 β en lisados de hipocampo.

Conclusión. Los resultados del estudio sugieren un efecto antiinflamatorio de la quercetina en la región CA1 del hipocampo en un modelo en ratón triple trasgénico para la enfermedad de Alzheimer.

Palabras clave: enfermedad de Alzheimer; quercetina; microglía; astrocitos.

doi: <https://doi.org/10.7705/biomedica.v38i0.3761>

Corresponding author:

Gloria Patricia Cardona-Gómez, Sede de Investigación
Universitaria (SIU), Universidad de Antioquia, Calle 62 N° 52-
59, torre 1, piso 4, laboratorio 412, Medellín, Colombia
Telephone: (574) 219 6458; fax: (574) 219 6444
patricia.cardonag@udea.edu.co

Received: 30/01/17; accepted: 04/07/17

Author's contributions:

Felipe Vargas-Restrepo: experiments and drafting of the manuscript

Angélica María Sabogal-Guáqueta: experiment' supervision

Gloria Patricia Cardona-Gómez: critical revision

All authors analyzed the data and participated in the review and approval of the final version of the manuscript.

Alzheimer's disease is the most common form of dementia, which is characterized by a progressive loss of memory and other cognitive functions. Its main histopathological hallmarks are extracellular beta-amyloid (β A) accumulation in senile plaques and intracellular hyperphosphorylated tau protein

forming neurofibrillary tangles (1). These aggregates induce an inflammatory response by the microglia and astrocytes that allow a gradual activation and subsequent production of pro-inflammatory mediators leading to neurodegeneration (2).

Microglial cells and astrocytes are involved in the inflammatory response in the central nervous system (CNS). Microglia remain in a resting state exhibiting a branched morphology; once they are activated by the presence of β A the size of the soma in the cell increases and the number of processes decreases acquiring an amoeboid form with absence or presence of shorter branches (3). Their ability to engulf β A peptides reduces while the production of pro-inflammatory mediators increases (3,4). Astrocytes also have a ramified morphology when they are in resting state, but after the onset of the Alzheimer's disease, they acquire a hypertrophic morphology with a reduction of branches and processes, and an increased cell soma (5). As is the case for microglia, astrocytes increase the production of pro-inflammatory mediators when they are activated (6).

Among the most important inflammatory mediators produced by microglial cells and astrocytes in Alzheimer's disease are the interleukin 1β (IL- 1β), the inducible nitric oxide synthase (iNOS) and the cyclooxygenase 2 (COX-2). IL- 1β is produced by those cells surrounding β A plaques (7), and it can modulate tau hyperphosphorylation through activated microglia and p38-MAPK activation (7,8). The other inflammatory mediator involved in neuroinflammation in the disease is iNOS. This enzyme is expressed in response to immunological challenges or by damaged tissue producing nitric oxide (NO) (9), which causes DNA damage and induces the production of peroxynitrites that destroy the mitochondria and reduce ATP formation (10). High levels of β A increase iNOS expression and NO production in microglia and astrocytes (9,11). COX-2 is an inducible enzyme in pathological conditions and it catalyzes the synthesis of prostaglandins, many of which are neurotoxic, such as prostaglandin E_2 (PGE $_2$), which is the main produced inflammatory prostaglandin (12). β A peptides induce the activation of PGE $_2$ in astrocytes and microglia (6,12), which can produce an increase in astrocyte proliferation *in vivo* and diminish the ability of microglia to phagocytose β A peptides (13,14).

Quercetin is a molecule with neuroprotective properties which may increase the neuronal resistance against oxidative stress by β A (15,16). In our previous studies, we have demonstrated that

quercetin reduces histopathological hallmarks improving cognitive and emotional skills in a 3xTg-AD mice model (17). Given that the hippocampus CA1 region is a vulnerable area for excitotoxicity and neuronal death in Alzheimer's disease (18), in this study we evaluated the effect of quercetin on the pro-inflammatory response.

Materials and methods

Animals

Male and female homozygous 3xTg-AD for APP (Swe), tau (P301L), PS1 (M146V), and knocking-PS1 mice (Non-3xTg) (M146V) (19) from our in-house colony were maintained at the specific pathogen-free vivarium of the *Sede de Investigación Universitaria* at the *Universidad de Antioquia* in Medellín. We assigned animals of 18 to 21 months of age randomly to the vehicles (DMSO) or quercetin groups regardless of their transgenic or non-transgenic condition (non-Tg). 3xTg-AD mice had a homogenous β -amyloidosis and tauopathy penetrance.

The animals were handled according to Colombian standards and guidelines (Law 84/1989 and Resolution 8430/1993); the protocol was approved by the Ethics Committee of the *Universidad de Antioquia* for animal experimentation. Special care was taken to minimize animal suffering and to reduce the number of animals used.

Administration of drugs

The 3xTg-AD and non-Tg mice received 25 mg/kg intraperitoneal injections of quercetin or 0.1% DMSO every 48 hours for three consecutive months, as previously described (17).

Histology and immunohistochemistry

Animals were intracardially perfused using 4% paraformaldehyde, and 50 μ m coronal sections were used for Nissl (toluidine blue) staining and immunohistochemistry evaluation as previously described (17). We assessed the CA1 region at bregma -1.82 and -2.06 mm. Anti-GFAP (1:1000, Sigma # G3893), anti-iNOS (1:250, C-11, Santa Cruz Biotechnology, Sc # 7271) (permeabilizing tissues 10 mM Tris pH 6, overnight at 4°C) were the mouse primary antibodies used together with the Iba1 anti-rabbit primary antibody (1:500, Wako # 019-19741) as microglia and COX-2 markers (1:500, # AB15191, Abcam).

To determine immunoreactivity (IR) densitometry we used a 10X objective and we analyzed it with the Fiji ImageJ 1.45 software (NIH, USA) based on

staining intensity. The number of animals per group was three in non-Tg quercetin animals and four in the other groups.

Immunofluorescence

We rinsed 50 μ m coronal sections at bregma -1.82 and -2.06 mm in 0.1 M PBS following a previously published protocol (20). Sections were incubated with β -amyloid anti-mouse primary antibody (1:500, β amyloid 1-16 (6E10) # SIG-39320, Covance), and Iba1 anti-rabbit primary antibody (1:500, # 019-19741, Wako). We analyzed the sections by using a motorized spinning disk confocal microscope (Olympus IX81-DSU). The omission of the primary antibodies resulted in no staining. Camera exposure time and gain were adjusted so that no pixel saturation was present in any channel, and identical camera settings were used for all images in each experiment.

Immunofluorescence (IF) was determined using a 10X objective and analyzed by Fiji ImageJ 1.45 software (NIH, USA) based on staining intensity. We processed all experimental groups at the same time for minimizing variability. The number of animals per group was three for non-Tg quercetin animals and four for the other groups.

ELISA IL-1 β

We measured IL-1 β using the Quantikine ELISA Mouse IL-1 β kitTM (Cat. # MLB00C, R&D Systems, Minneapolis, USA) following the manufacturer's protocol with a peptide concentration of 50 μ g/ml. The number of animals per group was two for 3xTg-DMSO animals and four for the other groups.

Western blotting

The procedure was performed as described previously (17). Briefly, anti-NOS2, anti-COX2, and anti-Tubulin (1:10000, monoclonal anti- β III tubulin, # G712A, Promega, AB_430874) were used as loading control, and CW IRDye 680 goat anti-mouse or rabbit 800 (LI-COR, diluted 1: 10000) were used as secondary antibodies. Fluorescence intensity was analyzed using the Odyssey Infrared Imaging SystemTM application software, version 3.0 (LI-COR, ODY-1735). We used four animals in each group.

Statistical analysis

We randomly processed the data collected. We used at least three mice in each group for histological evaluation and four in each group for biochemical analyses. We evaluated data with a normal

distribution using analysis of variance (ANOVA) to compare the four experimental groups, and then Tukey's test as post-hoc multiple comparison when appropriate. When the conditions of normality of the data distribution and variances were not normal we used the nonparametric Kruskal-Wallis test. The statistical analysis was performed using GraphPad Prism software (version 6.0), and results were considered to be significant at $p \leq 0.05$. The values were expressed as the mean \pm SEM.

Results

Quercetin reduces β -amyloid aggregation and microglial immunoreactivity in aged 3xTgAD mice.

We confirmed an increased fluorescence intensity (FI) of the microglial population and β A plaques in 3xTg-AD mice compared to non-Tg animals (figure 1A). Interestingly, quercetin treatment reduced significantly the Iba-1 (34%) and β A (48%) FI in the CA1 region of aged 3xTg-AD mice compared to untreated 3xTg-AD mice (figure 1B,C). Microglia showed increased cell body size similar to amoeboid shape in untreated 3xTgAD mice, which was blocked by the quercetin treatment in aged animals (figure 1A).

Quercetin ameliorates astrogliosis in aged 3xTgAD mice.

We qualitatively assessed pyramidal layer of the CA1 area in relation to the cell cytoarchitecture and the presence of microglial cells using a Nissl-Iba1 IR counterstaining. We detected an increased cellular condensation and irregular morphology in aged 3xTgAD mice surrounded by Iba1+ cells (figure 2A). These observations were supported by hypertrophied astrocytes, which showed a significant increase in the GFAP immunoreactivity (33%), compared with untreated and treated control groups (figure 2B). However, with the quercetin treatment mice recovered a similar morphological shape and reactivity in the CA1 area to those of control groups (figure 2 A, B).

Inflammatory mediators are down-regulated by quercetin in the CA1 area of 3xTgAD mice hippocampus.

The hippocampus CA1 area of 3xTgAD mice showed a significant increase of iNOS immunoreactivity with a diffuse distribution in the parenchyma (figure 3A, B). COX-2 reactivity also showed a vessel-like elongated pattern, which significantly increased in the Alzheimer's disease model (figure 3A, C).




Figure 1. Quercetin reduced the Iba-1 and β A fluorescence intensities in CA1 area of aged 3xTg-AD mice. **(A)** Immunofluorescence microglial (green) and β A plaques (red) from CA1 region. 10X and 60X; scale bar: 50 μ m and 5 μ m, respectively. **(B)** Fluorescence intensity quantification of Iba-1 positive cells. 10X. **(C)** Fluorescence intensity quantification in aggregates β A 10X. Data presented as mean \pm SEM. n: 3-4, * ($p < 0.05$) ** ($p = 0.001$), *** ($p < 0.001$)




Figure 2. Quercetin recovered altered cell cytoarchitecture and ameliorated astrogliosis in the CA1 area from aged 3xTgAD mice. **A)** Representative images of Nissl-Iba-1 counterstaining. **B)** GFAP immunohistochemistry for astrocytes, and quantification of GFAP immunoreactivity shown as densitometric relative units (RU) in CA1. 10X and 40X; scale bar: 50 μ m and 15 μ m, respectively. Data expressed as the mean \pm SEM. n: 3-4. ** $p < 0.01$

Quercetin-treated mice presented a significant reduction in immunostaining in the CA1 area (figure 3A,B,C), supported by normal IL-1 β levels in comparison to the untreated 3xTg-AD group and similar to the control groups (figure 3 D). However, hippocampal total lysates did not show significant changes in the iNOS and COX-2 protein levels (figure 3 E).

Discussion

Findings suggested a reduction of the pro-inflammatory response in the CA1 hippocampal region of aged 3xTg-AD mice with the use of quercetin, confirming our recent results where quercetin reversed β -amyloidosis and tauopathy associated to cognitive and emotional behavioral improvement (17).




Figure 3. Proinflammatory indicators were reduced by quercetin treatment in the CA1 area of 3xTgAD mice hippocampus. **A)** iNOS and COX-2 immunohistochemistry in CA1 region. 10X and 40X; scale bar: 50 μ m and 15 μ m, respectively. **B)** iNOS, and **C)** COX-2 immunoreactivity quantification at 10X. **D)** IL-1 β hippocampal lysate quantification in non-Tg and Tg mice with DMSO and QC treatment. **E)** Representative bands of iNOS and COX-2 in hippocampal lysates and densitometric quantification of iNOS and COX-2. Tubulin was used as control load. Immunohistochemistry (n: 3-5) and ELISA (n: 2-4). Data presented as mean \pm SEM. * ($p < 0.05$) ** ($p = 0.001$), *** ($p < 0.001$). For Western blotting, data are presented as mean \pm SEM. n=4, ($p < 0.005$)

In a pathological context, β A aggregates can activate microglia cells and astrocytes generating local inflammation and amplifying neuronal death signaling (21). In our study, the CA1 hippocampal area of aged 3xTgAD mice presented a pro-inflammatory environment marked by β -amyloid plaques surrounded by microgliosis associated to hypertrophied astrocytes and condensed pyramidal layer. These changes were accompanied by the up-regulation of IL-1 β , COX-2, and iNOS, which could be specific for the CA1 area, as they were not detected in the total hippocampal lysates.

Human Alzheimer's disease and models are characterized by a high microglial hyperreactivity (1,3), which increases the release of proinflammatory

cytokines and decreases β A clearance (4,22). For this reason, IL-1 β stimulates the production of COX-2 by microglial cells in brains affected by Alzheimer's disease (23), which favors the expression of iNOS through PGE₂ production (24), although IL-1 β also directly activates before iNOS (7). In a positive feedback, PGE₂ also induces microgliosis and this promotes astrocyte proliferation (13). Recently, it was found that microglial-specific deletion of PGE₂ restores microglial chemotaxis and β A clearance suppresses toxicity of the exacerbated pro-inflammatory response and microglial activation (25,26). On the other hand, astrocytes reactivated by their interaction with β A release IL-1 β , iNOS, and COX-2 amplifying the immune response (5,6,12). This

exacerbated reactivity causes astrocyte atrophy, which may also result in a reduced proteolytic clearance of β A and contribute to the extracellular β A accumulation and the decrease of neuronal support (27-29).

Our findings suggest that the quercetin treatment induced an anti-inflammatory response confirming previous studies where the compound decreases the production of inflammatory mediators such as iNOS, NO, COX-2, PGE₂, and IL-1 β and reduces the activation of microglia and astrocytes (30-33). Furthermore, quercetin contributes to the reduction of oxidative stress, since it increases the production of antioxidant enzymes in astrocytes, microglia and neurons (34,35). Thus, quercetin might help to inhibit the feedback among proinflammatory mediators and glial cells avoiding the spreading of neuronal damage.

Interestingly, our results showed that the quercetin treatment also reverses the immune response in an advanced stage of the disease in the model under study. This suggests that the induction of β A phagocytosis (4,36) and the decrease in the release of neurotoxic cytokines (2) are mediating the protective action of quercetin, because in our previous observations quercetin did not regulate typical tauopathy mediator enzymes, such as CDK5 and GSK3-beta (17). However, quercetin might reduce tauopathy by the regulation of IL-1 β /p38 MAPK activation (8) and, thus, improve cognitive performance (17). Other protective effects have been described for quercetin in restoring the expression of genes perturbed by β A accumulation including DNA replication, cell cycle proteins, hypoxia response, *de novo* pyrimidine deoxyribonucleotide biosynthesis, p53 pathway and β A metabolism regulation and in decreasing β A40 and β A42 species by the stabilization of astrocytes-derived apolipoprotein E (37,38).

Our work suggests an anti-inflammatory effect of quercetin in hippocampal CA1 region in a model for Alzheimer's disease of triple transgenic aged mice by reducing β -amyloid plaques aggregation and microglial and astroglial reactivity as reflected in the decrease of IL-1 β / COX-2/ iNOS pro-inflammatory signaling, which could be closely related to previous findings on the reversal of tauopathy, as well as emotional and cognitive impairment.

Acknowledgements

The authors would like to thank the *Grupo de Neurociencias de Antioquia, Facultad de Medicina,*

Universidad de Antioquia, and the Group of Bio-active Substances for their scientific and technical support during the experiments.

Conflicts of interest

The authors declare they have no competing interests.

Financing

This research was funded by grants from Colciencias (# 111551928905) (GPC-G), the *Universidad de Antioquia* CODI, and Colciencias' program for young researchers (2011e2012) (AM S-G).

References

1. Querfurth HW, LaFerla FM. Alzheimer's disease. *N Engl J Med.* 2010;362:329-44. <https://doi.org/10.1056/NEJMr0909142>
2. Morales I, Guzmán-Martínez L, Cerda-Troncoso C, Fariás GA, Maccioni RB. Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. *Front Cell Neurosci.* 2014;8:1-9 <https://doi.org/10.3389/fncel.2014.00112>
3. Baron R, Babcock AA, Nemirovsky A, Finsen B, Monsonego A. Accelerated microglial pathology is associated with A β plaques in mouse models of Alzheimer's disease. *Aging Cell.* 2014;13:584-95. <https://doi.org/10.1111/ace.12210>
4. Hickman SE, Allison EK, El Khoury J. Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. *J Neurosci.* 2008;28:8354-60. <https://doi.org/10.1523/JNEUROSCI.0616-08.2008>
5. Rodríguez JJ, Olabarria M, Chvatal A, Verkhratsky A. Astroglia in dementia and Alzheimer's disease. *Cell Death Differ.* 2008;16:378-85. <https://doi.org/10.1038/cdd.2008.172>
6. Carrero I, Gonzalo MR, Martín B, Sanz-Anquela JM, Arévalo-Serrano J, Gonzalo-Ruiz A. Oligomers of beta-amyloid protein (A β 1-42) induce the activation of cyclooxygenase-2 in astrocytes via an interaction with interleukin-1 β , tumour necrosis factor- α , and a nuclear factor kappa-B mechanism in the rat brain. *Exp Neurol.* 2012;236:215-27. <https://doi.org/10.1016/j.expneurol.2012.05.004>
7. Rubio-Pérez JM, Morillas-Ruiz JM. A review: Inflammatory process in Alzheimer's disease, role of cytokines. *Sci World J.* 2012;2012:1-15. <https://doi.org/10.1100/2012/756357>
8. Li Y, Liu L, Barger SW, Griffin WS. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. *J Neurosci.* 2003;23:1605-11.
9. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. *Physiol Rev.* 2007;87:315-424. <https://doi.org/10.1152/physrev.00029.2006>
10. Schopfer F. NO-dependent protein nitration: A cell signaling event or an oxidative inflammatory response? *Trends Biochem Sci.* 2003;28:646-54. <https://doi.org/10.1016/j.tibs.2003.10.006>

11. **Klegeris A, Walker DG, McGeer PL.** Activation of macrophages by Alzheimer β amyloid peptide. *Biochem Biophys Res Commun.* 1994;199:984-91. <https://doi.org/10.1006/bbrc.1994.1326>
12. **Heneka MT, O'Banion MK, Terwel D, Kummer MP.** Neuroinflammatory processes in Alzheimer's disease. *J Neural Transm.* 2010;117:919-47. <https://doi.org/10.1007/s00702-010-0438-z>
13. **Zhang D, Hu X, Qian L, Wilson B, Lee C, Flood P, et al.** Prostaglandin E2 released from activated microglia enhances astrocyte proliferation in vitro. *Toxicol Appl Pharmacol.* 2009;238:64-70. <https://doi.org/10.1016/j.taap.2009.04.015>
14. **Nagano T, Kimura SH, Takemura M.** Prostaglandin E2 reduces amyloid β -induced phagocytosis in cultured rat microglia. *Brain Res.* 2010;1323:11-7. <https://doi.org/10.1016/j.brainres.2010.01.086>
15. **Kanter M, Unsal C, Aktas C, Erboga M.** Neuroprotective effect of quercetin against oxidative damage and neuronal apoptosis caused by cadmium in hippocampus. *Toxicol Ind Health.* 2013;32:541-50. <https://doi.org/10.1177/0748233713504810>
16. **Ansari MA, Abdul HM, Joshi G, Opii WO, Butterfield DA.** Protective effect of quercetin in primary neurons against $A\beta(1-42)$: Relevance to Alzheimer's disease. *J Nutr Biochem.* 2009;20:269-75. <https://doi.org/10.1016/j.jnutbio.2008.03.002>
17. **Sabogal-Guáqueta AM, Muñoz-Manco JI, Ramírez-Pineda JR, Lamprea-Rodríguez M, Osorio E, Cardona-Gómez GP.** The flavonoid quercetin ameliorates Alzheimer's disease pathology and protects cognitive and emotional function in aged triple transgenic Alzheimer's disease model mice. *Neuropharmacology.* 2015;93:134-45. <https://doi.org/10.1016/j.neuropharm.2015.01.027>
18. **Aronica E, Dickson D, Kress Y, Morrison J, Zukin R.** Non-plaque dystrophic dendrites in Alzheimer hippocampus: A new pathological structure revealed by glutamate receptor immunocytochemistry. *Neuroscience.* 1998;82:979-91. [https://doi.org/10.1016/S0306-4522\(97\)00260-1](https://doi.org/10.1016/S0306-4522(97)00260-1)
19. **Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kaye R, et al.** Triple-transgenic model of Alzheimer's disease with plaques and tangles. *Neuron.* 2003;39:409-21. [https://doi.org/10.1016/S0896-6273\(03\)00434-3](https://doi.org/10.1016/S0896-6273(03)00434-3)
20. **Gutiérrez-Vargas J, Castro-Álvarez JF, Velásquez-Carvajal D, Montañez-Velásquez MN, Céspedes-Rubio Á, Cardona-Gómez GP.** Rac1 activity changes are associated with neuronal pathology and spatial memory long-term recovery after global cerebral ischemia. *Neurochem Int.* 2010;57:762-73. <https://doi.org/10.1016/j.neuint.2010.08.014>
21. **Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH.** Mechanisms underlying inflammation in neurodegeneration. *Cell.* 2010;140:918-34. <https://doi.org/10.1016/j.cell.2010.02.016>
22. **von Bernhardi R, Ramírez G, Toro R, Eugénin J.** Pro-inflammatory conditions promote neuronal damage mediated by Amyloid Precursor Protein and decrease its phagocytosis and degradation by microglial cells in culture. *Neurobiol Dis.* 2007;26:153-64. <https://doi.org/10.1016/j.nbd.2006.12.006>
23. **Wang P, Guan P-P, Wang T, Yu X, Guo J-J, Wang Z-Y.** Aggravation of Alzheimer's disease due to the COX-2-mediated reciprocal regulation of IL-1 β and $A\beta$ between glial and neuron cells. *Aging Cell.* 2014;13:605-15. <https://doi.org/10.1111/acer.12209>
24. **Quan Y, Jiang J, Dingledine R.** EP2 receptor signaling pathways regulate classical activation of microglia. *J Biol Chem.* 2013;288:9293-302. <https://doi.org/10.1074/jbc.M113.455816>
25. **Johansson JU, Woodling NS, Wang Q, Panchal M, Liang X, Trueba-Saiz A, et al.** Prostaglandin signaling suppresses beneficial microglial function in Alzheimer's disease models. *J Clin Invest.* 2015;125:350-64. <https://doi.org/10.1172/JCI77487>
26. **Dá Mesquita S, Ferreira AC, Sousa JC, Correia-Neves M, Sousa N, Marques F.** Insights on the pathophysiology of Alzheimer's disease: The crosstalk between amyloid pathology, neuroinflammation and the peripheral immune system. *Neurosci Biobehav Rev.* 2016;68:547-62. <https://doi.org/10.1016/j.neubiorev.2016.06.014>
27. **Heppner FL, Ransohoff RM, Becher B.** Immune attack: The role of inflammation in Alzheimer disease. *Nat Rev Neurosci.* 2015;16:358-72. <https://doi.org/10.1038/nrn3880>
28. **Steele ML, Robinson SR.** Reactive astrocytes give neurons less support: Implications for Alzheimer's disease. *Neurobiol Aging.* 2012;33:423. <https://doi.org/10.1016/j.neurobiolaging.2010.09.018>
29. **Orre M, Kamphuis W, Osborn LM, Jansen AH, Kooijman L, Bossers K, et al.** Isolation of glia from Alzheimer's mice reveals inflammation and dysfunction. *Neurobiol Aging.* 2014;35:2746-60. <https://doi.org/10.1016/j.neurobiolaging.2014.06.004>
30. **Kang C-H, Choi YH, Moon S-K, Kim W-J, Kim G-Y.** Quercetin inhibits lipopolysaccharide-induced nitric oxide production in BV2 microglial cells by suppressing the NF- κ B pathway and activating the Nrf2-dependent HO-1 pathway. *Int Immunopharmacol.* 2013;17:808-13. <https://doi.org/10.1016/j.intimp.2013.09.009>
31. **Sharma V, Mishra M, Ghosh S, Tewari R, Basu A, Seth P, et al.** Modulation of interleukin-1 β mediated inflammatory response in human astrocytes by flavonoids: Implications in neuroprotection. *Brain Res Bull.* 2007;73:55-63. <https://doi.org/10.1016/j.brainresbull.2007.01.016>
32. **Lu J, Wu D, Zheng Y, Hu B, Zhang Z, Shan Q, et al.** Quercetin activates AMP-activated protein kinase by reducing PP2C expression protecting old mouse brain against high cholesterol-induced neurotoxicity. *J Pathol.* 2010;222:199-212. <https://doi.org/10.1002/path.2754>
33. **Sung M-S, Lee E-G, Jeon H-S, Chae H-J, Park SJ, Lee YC, et al.** Quercetin inhibits IL-1 β -induced proliferation and production of MMPs, COX-2, and PGE2 by rheumatoid synovial fibroblast. *Inflammation.* 2012;35:1585-94. <https://doi.org/10.1007/s10753-012-9473-2>
34. **Lavoie S, Chen Y, Dalton TP, Gysin R, Cuénod M, Steullet P, et al.** Curcumin, quercetin, and tBHQ modulate glutathione levels in astrocytes and neurons: Importance of the glutamate cysteine ligase modifier subunit. *J Neurochem.* 2009;108:1410-22. <https://doi.org/10.1111/j.1471-4159.2009.05908.x>

35. **Chen JC, Ho FM, Pei-Dawn LC, Chen C-P, Jeng K-CG, Hsu HB, *et al.*** Inhibition of iNOS gene expression by quercetin is mediated by the inhibition of I κ B kinase, nuclear factor-kappa B and STAT1, and depends on heme oxygenase-1 induction in mouse BV-2 microglia. *Eur J Pharmacol.* 2005;521:9-20. <https://doi.org/10.1016/j.ejphar.2005.08.005>
36. **Krabbe G, Halle A, Matyash V, Rinnenthal JL, Eom GD, Bernhardt U, *et al.*** Functional impairment of microglia coincides with beta-amyloid deposition in mice with Alzheimer-like pathology. *PLoS One.* 2013;8:e60921. <https://doi.org/10.1371/journal.pone.0060921>
37. **Zhang X, Hu J, Zhong L, Wang N, Yang L, Liu C-C, *et al.*** Quercetin stabilizes apolipoprotein E and reduces brain A β levels in amyloid model mice. *Neuropharmacology.* 2016;108:179-92. <https://doi.org/10.1016/j.neuropharm.2016.04.032>
38. **Kong Y, Li K, Fu T, Wan C, Zhang D, Song H, *et al.*** Quercetin ameliorates A β toxicity in *Drosophila* AD model by modulating cell cycle-related protein expression. *Oncotarget.* 2016;7:67716-31. <https://doi.org/10.18632/oncotarget.11963>